This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

P. J. HANZLIK, M.D.; H. G. MEHRTENS, M.D.; D. C. MARSHALL, M.D.; FRANCES WATSON, A.B.; JEAN SPAULDING, A.M.

Arch Derm Syphilol. 1930;22(3):483-495.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The excretion of bismuth has been studied chiefly in animals. The clinical excretion of most of the products used currently in the treatment of patients with syphilis has not been determined. Certain products used by foreign investigators in studies of clinical excretion are not used in this country, and some of them are trade-marked specialties of unknown or uncertain composition. We have recorded a total of fifty-six different products reported in the literature, and one investigator¹ claims to have prepared twenty-four organic bismuthyl derivatives. There might be, therefore, a total of eighty products of bismuth which have been or may be offered to physicians for use in the treatment for syphilis. Most of these products have little or nothing original to offer and are superfluous. In view of these circumstances, it appeared desirable to undertake studies of typical representatives of bismuth products under clinical conditions.

All products of bismuth . . . [Full Text PDF of this Article]

Author Affiliations
SAN FRANCISCO

From the Department of Pharmacology and the Neuropsychiatric Division of the Department of Medicine, Stanford University School of Medicine.

Footnotes
Submitted for publication, March 10, 1930.

This study was supported by grant from the Committee on Research in Syphilis, Inc.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?